We apply our knowledge gained from years of IND research and innovative technologies to help you successfully initiate and complete your IND-enabling program.
Given the specialized nature of biologic development, you’ll benefit from the broadest set of capabilities across the industry. With full-service capabilities, Accelera provides you access to end-to-end preclinical solutions.
Combining years of experience in the development of biologic products with a deep knowledge of regulatory requirements, we can support our clients’ biosimilar programs with in vivo preclinical studies and preclinical and clinical sample analysis.
Cell and gene therapies are classified as an advanced therapy medicinal products (ATMPs), these are subject to specific regulations and requires sophisticated testing technologies to bring to market. From regulatory expertise to a comprehensive portfolio of preclinical services, you’ll find everything you need to make your cell and gene therapies a reality at Accelera.